cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Dyne Therapeutics Inc
9 own
5 watching
Current Price
$25.46
$1.9
(8.06%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,339.81M
52-Week High
52-Week High
47.45000
52-Week Low
52-Week Low
12.33000
Average Volume
Average Volume
1.13M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
-1.35986159
iconMarket Capitalization3,339.81M
icon52-Week High47.45000
icon52-Week Low12.33000
iconAverage Volume1.13M
iconDividend Yield--
iconP/E Ratio-1.35986159
What does the Dyne Therapeutics Inc do?
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Read More
How much money does Dyne Therapeutics Inc make?
News & Events about Dyne Therapeutics Inc.
Zolmax
1 year ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Joshua T. Brumm sold 76,582 shares of Dyne Therapeutics stock in a transaction on Friday, June 9th. The shares were sold at an average price of $13.34, for a total value of $1,021,603.88. Following the completion of the transaction, the insider...
Globe Newswire
1 year ago
- Company Presents Overviews of ACHIEVE and DELIVER Global Clinical Trials with Data Anticipated from Both Studies in the Second Half of 2023 - - FORCEPlatform Achieves Robust Exon Skipping, Restores Dystrophin at the Sarcolemma and Halts Progression of Fibrosis in a Severe In Vivo Model of Duchenne...
Globe Newswire
1 year ago
- Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD - WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing ...
Ticker Report
1 year ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
Ticker Report
1 year ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
Frequently Asked Questions
Frequently Asked Questions
What is Dyne Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Dyne Therapeutics Inc shares?
plus_minus_icon
How can I buy Dyne Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Dyne Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Dyne Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Dyne Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Dyne Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Dyne Therapeutics Inc?
plus_minus_icon
What percentage is Dyne Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Dyne Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$25.46
$1.9
(8.06%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
REVOLUTION Medicines Inc
REVOLUTION Medicines Inc
$44.00
$0.26 (0.59 %)
Westlake Chemical Partners
Westlake Chemical Partners
$23.00
$-0.14 (-0.61 %)
Orion Engineered Carbons S.A.
Orion Engineered Carbons S.A.
$15.27
$-0.52 (-3.29 %)
Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
$1.60
$0.07 (4.58 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
REVOLUTION Medicines Inc
REVOLUTION Medicines Inc
$44.00
$0.26 (0.59 %)
Westlake Chemical Partners
Westlake Chemical Partners
$23.00
$-0.14 (-0.61 %)
Orion Engineered Carbons S.A.
Orion Engineered Carbons S.A.
$15.27
$-0.52 (-3.29 %)
Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
$1.60
$0.07 (4.58 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00